首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1754283

细胞激素市场规模、份额、趋势及预测（按细胞激素类型、治疗应用、最终用户和地区），2025 年至 2033 年

Cytokine Market Size, Share, Trends and Forecast by Cytokine Type, Therapeutic Application, End User, and Region, 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

2024 年全球细胞激素市场规模为 957 亿美元。展望未来， IMARC Group估计，到 2033 年，市场规模将达到 1,723.6 亿美元，2025-2033 年期间的复合年增长率为 6.42%。北美目前占据市场主导地位，2024 年将占据约 62.9% 的显着市场。自体免疫疾病、癌症和发炎性疾病发生率的上升推动了市场的发展，从而增加了对细胞激素疗法的需求。此外，生物技术的发展，包括靶向细胞激素疗法和单株抗体的发现，正在推动市场扩张。此外，对研发 (R&D) 的投资增加以及政府为推广创新治疗方法所做的努力，都是增加细胞激素市场份额的主要因素。

自体免疫疾病、癌症和发炎性疾病的发生率不断上升，导致市场对细胞激素治疗产品的需求不断增加，这推动了市场的发展。此外，免疫疗法研究的蓬勃发展也促进了新型细胞激素疗法的开发，从而加深了人们对疾病机制和治疗效果的理解。例如，Foresite Capital 于2024年6月27日成立了一支新基金，专注于突破性技术，包括生物技术和科技领域的技术。 Bright Peak Therapeutics 在B轮融资中筹集了1.07亿美元，由RA Capital领投，多家投资者参与。该公司正在推进其用于合成治疗性细胞因子的新型平台，该平台能够增强细胞因子的生物学特性，并透过将细胞因子与特定抗体结合，创造出专有的「Bright Peak免疫细胞因子」。此外，监管部门对生物技术产品的支持也加速了细胞激素疗法的接受度，这对细胞激素市场前景产生了积极影响。

在美国，癌症和类风湿性关节炎等慢性病的日益普及推动了市场的发展，导致对标靶治疗的需求增加。根据行业报告，关节炎影响美国很大一部分成年人口，目前受影响的人数超过 5800 万，其中一半处于工作年龄。到 2040 年，美国患有关节炎的成年人口预计将增加至 7,800 万人。完善的医疗基础设施和高水准的医疗支出也刺激了市场的发展。此外，对生物製药研究（特别是在免疫肿瘤学和免疫治疗领域）的大量投资也导致了细胞激素开发和研究的增加。除此之外，不断变化的监管环境和对临床试验的鼓励对于推动基于细胞因子的疗法的批准也具有重要意义。

细胞激素市场趋势：

冠状病毒病（COVID-19）的影响

疫情对市场产生了重大影响，尤其体现在对细胞激素相关疗法的需求增加。在整个疫情期间，COVID-19 患者往往会出现严重的发炎反应，例如细胞激素风暴，这会导致併发症并增加死亡率。世界卫生组织 (WHO) 于 2024 年 6 月报告称，自疫情爆发以来，全球累计确诊病例超过 7.75 亿，死亡人数超过 700 万人。因此，针对此类反应的细胞激素标靶疗法备受关注。此外，疫情推动了单株抗体和细胞激素抑制剂的改进和研发，这些药物在控制 COVID-19 引起的发炎方面的疗效也得到了评估。此外，针对 COVID-19 患者进行细胞激素调节的临床试验，为细胞激素靶向干预措施提供了新的见解。这为基于细胞因子的疗法开闢了新的研究视野，使细胞激素疗法成为对抗传染病的关键武器。

癌症发生率不断上升

全球癌症发生率的上升是细胞激素市场成长的主要驱动力之一。根据 NCBI 的数据，到 2050 年，全球癌症病例预计将达到 3,530 万，比 2022 年估计的 2,000 万增加 76.6%。同样，癌症死亡人数预计将达到 1850 万，比 2022 年估计的 970 万增加 89.7%。细胞激素在免疫反应和调节中发挥着至关重要的作用，它们在肿瘤发展和免疫逃脱中的作用使其成为癌症研究的中心主题。免疫疗法，包括基于细胞因子的疗法，越来越多地被纳入对常规疗法有抗药性的癌症的治疗中。此外，细胞激素疗法也在黑色素瘤、肺癌和肾细胞癌等其他类型癌症中进行研究，旨在增强免疫监视和抗肿瘤活性。越来越多的临床试验和基于细胞因子的疗法的发展表明这些药物将成为未来癌症治疗不可或缺的一部分。

扩大阿兹海默症（AD）研究

随着对神经发炎及其在疾病进展中的关键作用的研究不断深入，细胞因子在阿兹海默症 (AD) 中的作用已引起广泛关注。 2021 年全球疾病负担 (GBD) 研究估计，2021 年全球约有 1.29 亿人患有 AD，预计到 2050 年这一数字将增至 1.48 亿。盛行率的上升反映了对有效治疗方案日益增长的需求。在阿兹海默症 (AD) 中，由细胞激素介导的脑内发炎过程被认为在神经元损伤和衰退中发挥作用。因此，抑制促发炎细胞激素（例如 TNF-a 和 IL-1B）已成为一种减少神经发炎和延缓疾病进展的新型治疗策略。最近的研究表明，调节这些细胞因子可能为治疗提供新的机会，从而激发了人们对基于细胞因子的疗法的兴趣。这促使製药公司投资研发新的细胞激素抑制剂和免疫调节剂，目前正在进行大量临床试验。

The global cytokine market size was valued at USD 95.70 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 172.36 Billion by 2033, exhibiting a CAGR of 6.42% during 2025-2033. North America currently dominates the market, holding a significant market share of around 62.9% in 2024. The market is fueled by the rising incidences of autoimmune conditions, cancer, and inflammatory diseases, which has increased the demand for cytokine therapies. Moreover, the developments in biotechnology, which include the discovery of targeted cytokine therapies and monoclonal antibodies, are driving market expansion. In addition, increased investments in research and development (R&D), as well as government efforts to promote innovative therapeutic approaches, are major factors augmenting the cytokine market share.

The market is driven by the growing incidences of autoimmune disorders, cancer, and inflammatory disorders that are inducing a greater need for cytokine therapeutic products. Moreover, the growth in research for immunotherapy is encouraging the development of new cytokine therapies, thereby increasing understanding of disease mechanisms and treatment effectiveness. For instance, on June 27, 2024, Foresite Capital launched a new fund focused on breakthrough technologies, including those in the biotech and technology sectors. Bright Peak Therapeutics raised USD 107 Million in Series B financing, led by RA Capital and supported by various investors. The company is advancing its novel platform for synthesizing therapeutic cytokines, which enables enhanced cytokine biology and the creation of proprietary "Bright Peak Immunocytokines" by conjugating cytokines with specific antibodies. Apart from this, the regulatory support for biotechnology products is also accelerating the acceptance of cytokine therapies, which positively impacts the cytokine market outlook.

In the US, the market is driven by the increasing prevalence of chronic diseases, including cancer and rheumatoid arthritis, which are causing the demand for targeted therapies to increase. According to industry reports, arthritis impacts a large segment of the adult population in the United States, with more than 58 million individuals currently affected, half of whom are in their working years. By 2040, the number of adults in the country who have arthritis is anticipated to increase to 78 million. The availability of established healthcare infrastructure and a high level of healthcare expenditure also fuels the market. Furthermore, a high level of investment in biopharmaceutical research, particularly in the fields of immuno-oncology and immunotherapy, has also led to an increase in cytokine development and research. Besides this, the changing regulatory landscape and the encouragement of clinical trials are also significant in propelling the approval of cytokine-based therapies.

Cytokine Market Trends:

Impact of Coronavirus Disease (COVID-19)

The pandemic had a significant impact on the market, particularly through increased demand for cytokine-associated therapeutics. Throughout the pandemic, COVID-19 patients tended to present severe inflammatory reactions, such as cytokine storms, that led to complications and increased mortality. In June 2024, the World Health Organization (WHO) reported over 775 million cases and over seven million deaths globally since the onset of the pandemic. Consequently, therapies for cytokine-targeting to control such responses increased interest. Moreover, the pandemic pushed forward the improvement and development of monoclonal antibodies and cytokine inhibitors, which were evaluated for their efficacy in controlling inflammation caused by COVID-19. Moreover, clinical trials for cytokine modulation in patients with COVID-19 give insights into cytokine-targeting interventions. This is opening up new research horizons for cytokine-based therapies, positioning cytokine therapeutics as crucial weapons in the fight against infectious diseases.

Increasing Prevalence of Cancer

The growing incidence of cancer across the globe is one of the key drivers of cytokine market growth. As per NCBI, by 2050, cancer cases worldwide are anticipated to reach 35.3 million, representing a 76.6% increase from the estimated 20 million in 2022. Likewise, cancer deaths are forecast to reach 18.5 million, showing an 89.7% growth compared to the 2022 estimate of 9.7 million. Cytokines play a crucial role in immune response and regulation, and their roles in tumor development and immune evasion have made them a central topic in cancer research. Immunotherapies, including those based on cytokines, are increasingly incorporated into the treatment of cancers resistant to conventional therapies. In addition to this, cytokine therapies are also studied in other types of cancers, such as melanoma, lung cancer, and renal cell carcinoma, where they seek to promote immune surveillance and anti-tumor activity. The increasing number of clinical trials and developments in cytokine-based therapies suggest that these drugs will be an integral part of cancer treatment in the future.

Expanding Alzheimer's Disease (AD) Research

Cytokine involvement in Alzheimer's Disease (AD) has gained significant attention due to the expanding research on neuroinflammation and its critical role in disease progression. The 2021 Global Burden of Disease (GBD) study estimated that approximately 129 million individuals across the globe lived with AD in 2021, and estimates suggest this will increase to 148 million by 2050. This rising prevalence reflects the escalating need for efficient therapeutic options. In Alzheimer's disease (AD), an inflammatory process in the brain, mediated by cytokines, is thought to play a role in neuronal injury and decline. Therefore, inhibition of pro-inflammatory cytokines, such as TNF-a and IL-1B, has emerged as a novel therapeutic strategy to reduce neuroinflammation and retard disease progression. Recent studies suggest that modulating these cytokines may provide new opportunities for treatment, thereby fueling interest in cytokine-based therapies. This has prompted pharmaceutical firms to invest in the discovery of new cytokine inhibitors and immunomodulators, and numerous clinical trials are currently ongoing.

Cytokine Industry Segmentation:

Analysis by Cytokine Type:

Tumor Necrosis Factor-TNF
Interleukins-Il
Interferons-IFN
Epidermal Growth Factor-EGF
Others

Tumor necrosis factor-TNF leads the market with around 57.6% of market share in 2024. The segment plays a pivotal role in inflammation and regulation of immune response. TNF is involved in the majority of autoimmune conditions, including rheumatoid arthritis, Crohn's disease, and psoriasis. One of the most widely used biological drugs is TNF inhibitors, which offer significant therapeutic value to patients suffering from chronic inflammatory diseases. With the growing demand for TNF-based therapy, this cytokine has been specifically in vogue in the market, and this has resulted in the creation of advanced biologics and monoclonal antibodies against TNF activity. With the potential to target TNF, therapeutic opportunities have evolved, offering patients viable alternatives to traditional therapy. The rising prevalence of autoimmune diseases globally leads to growth in the application of TNF in the cytokine market. The expansion of the segment is further driven by continuing pharmaceutical innovation and a robust pipeline of new TNF inhibitors.

Analysis by Therapeutic Application:

Cancer
Asthma and Airway Inflammation
Arthritis
Others

Arthritis leads the market with around 45.8% of market share in 2024 due to the widespread incidences of autoimmune forms such as rheumatoid arthritis (RA) and osteoarthritis (OA). In RA, excessive pro-inflammatory cytokine production, TNF, IL-6, and IL-1 are the underlying factors for inflammation and joint destruction. Therefore, cytokine-based therapies such as TNF inhibitors and interleukin inhibitors have emerged to play an important role in the management of such conditions. Biologics directly act on the cytokines responsible for the inflammatory process, alleviating pain, swelling, and chronic damage to the joints. The increasing prevalence of arthritis worldwide, along with the chronic nature of the disease, drives market expansion. The development of advanced treatments that are more efficient and have less negative impact is critical to expanding available therapeutic options for patients, ensuring that arthritis remains a key focus for cytokine-based treatment innovations. As a result, arthritis plays a major part in the market.

Analysis by End User:

Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes

Pharmaceutical and biotech firms are key end users in the market, spearheading the research and commercialization of cytokine therapies. Pharmaceutical and biotech firms invest heavily in research and development (R&D) activities focused on developing advanced biologics and cytokine inhibitors for the treatment of numerous diseases, such as autoimmune diseases, cancers, and inflammatory diseases. Their contribution is vital as these firms launch new cytokine-targeted therapies to market via clinical trials and approvals. The segment also forms partnerships, collaborations, and licensing deals, broadening their pipelines of products and facilitating the global supply of cytokine drugs. Pharmaceutical and biotech companies remain fundamental to the growth of the cytokine market as the need for personalized medicine and immunotherapies increases.

Contract Research Organizations (CROs) play a central role in the cytokine industry, aiding pharmaceutical and biotechnology firms with the research, development, and clinical evaluation of cytokine therapies. CROs offer critical services like clinical trial management, regulatory affairs, data analysis, and patient recruitment and assist in speeding up the development process of novel cytokine therapies. Their knowledge enables organizations to effectively perform preclinical and clinical trials in the face of the intricate regulatory landscape. With the advancement in cytokine therapies, CROs provide assurance that treatments go through severe testing, safety evaluation, and efficacy checks. The growing demand for cytokine-based therapies necessitates CROs, which enable the timely and economic development of these life-saving therapeutics.

Academic and research institutions form the backbone of the market as they are leading centers of basic and applied studies in immunology, cell biology, and cytokine-related therapies. These institutions carry out cutting-edge research on the mechanisms of cytokines and how they influence disease advancement, thereby paving the way for innovative therapeutic strategies. Several cytokine-based treatments available on the market today have stemmed from academic discoveries, which were subsequently developed into clinical uses by pharmaceutical companies. The institutes also partner with biotechnology companies and CROs, taking part in clinical trials and designing new treatment approaches. With increased emphasis on personalized and precision medicine, academic and research institutions will remain important drivers of future developments in the market.

Regional Analysis:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2024, North America accounted for the largest market share of over 62.9% due to superior healthcare infrastructure, strong research and development (R&D) spending, and a growing pharmaceutical sector. The region is a focal point for the development and commercialization of cytokine therapies, especially for autoimmune diseases, cancer, and inflammatory conditions. The need for biologics and cytokine inhibitors in North America is considerable, driven by high incidence of diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. North America also has regulatory systems that encourage fast-track approvals for new treatments, offering incentives for innovation, and creating a conducive environment for new cytokine therapies. With a heightened emphasis on precision medicine and immunotherapy, the region is still leading in cytokine-related clinical trials and drug development.

Key Regional Takeaways:

United States Cytokine Market Analysis

In 2024, the United States holds a substantial share of around 95.90% of the market share in North America. The market is primarily driven by the rising prevalence of autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. As per the National Center for Biotechnology Information (NCBI), approximately 1.3 million American adults, representing 0.6-1% of the adult population, are affected by rheumatoid arthritis (RA). Among these patients, the prevalence of work-related disabilities associated with RA is estimated to be around 35%. In addition to this, the increasing incidence of cancer, driving the need for cytokine-targeted immunotherapies, is propelling the market growth. Similarly, continual technological advancements in cytokine biology, along with the development of novel biologic drugs, are enhancing treatment options, further augmenting market expansion. The growing focus on personalized medicine is also promoting the adoption of tailored cytokine therapies for individual patients. Furthermore, the expansion of clinical trials dedicated to cytokine-related treatments is accelerating the market's momentum. The ongoing shift towards biologic drugs over traditional therapies is another significant market driver. Besides this, the rise in the aging population, with its higher incidence of chronic diseases, is constantly pushing the market demand for cytokine therapies.

Europe Cytokine Market Analysis

The market for cytokines in Europe is experiencing growth driven by the rising incidence of chronic diseases, such as cardiovascular conditions and diabetes. According to WHO, diabetes is a prevalent chronic condition in the WHO European Region, which has the highest global burden of type 1 diabetes. Around 74 million adults and 300,000 children and adolescents are affected by diabetes in the region. By 2045, it is projected that 1 in 10 people in the region will have diabetes. In accordance with this, the increasing prevalence of inflammatory diseases like multiple sclerosis and psoriasis is further strengthening market demand. The continual advances in biotechnology, particularly in gene editing and CRISPR technology, are enabling the development of more effective cytokine therapies. Furthermore, the growing focus on personalized medicine, fueling the need for immune-modulatory treatments, is impelling the market. The advancement in research and development funding in immunotherapy and cytokine drug discovery is also propelling market innovation. Additionally, enhanced healthcare infrastructure and improved access to advanced therapies across Europe are contributing to market expansion. Moreover, strategic collaborations between biotech companies and research institutions, fostering the development of novel therapies, are providing an impetus to the market.

Asia Pacific Cytokine Market Analysis

The Asia Pacific market is predominantly propelled by the increasing prevalence of infectious diseases, such as hepatitis and HIV. Similarly, the rapid growth of the biotechnology and pharmaceutical sectors, particularly in China and India, is fueling market expansion. The rising adoption of advanced healthcare technologies, including precision medicine and gene therapy, is encouraging the integration of cytokine-based treatments. Furthermore, increasing government investments in healthcare infrastructure and biotechnology research are creating opportunities for market development. According to IBEF, the Indian government allocated INR 99,858 Crore (USD 11.50 Billion) to the healthcare sector in the Union Budget 2025-26, marking a 9.78% increase from the previous allocation of INR 90,958 Crore (USD 10.47 Billion) in FY25. The increased awareness among healthcare professionals about immunotherapies and cytokine-based treatments is supporting market growth. Moreover, the rising demand for treatments in cancer and autoimmune diseases is further driving the need for cytokine therapies in the region.

Latin America Cytokine Market Analysis

In Latin America, the market is advancing, driven by increasing healthcare investments in countries like Brazil and Mexico. As such, in September 2024, Rede D'Or, Brazil's leading hospital group, planned to invest BRL 7.5 billion (USD 1.5 Billion) by 2028 to expand healthcare capacity. In line with this, the rising prevalence of chronic diseases such as diabetes and cancer is further contributing to growth in the market. Additionally, the expanding biotechnology sector, supported by government initiatives, is fostering innovation in cytokine treatments. Furthermore, the growing adoption of immunotherapy in cancer treatment is driving demand for cytokine-based therapies as healthcare providers seek more effective alternatives to traditional treatments to improve patient outcomes.

Middle East and Africa Cytokine Market Analysis

The market in the Middle East and Africa is significantly influenced by increasing government investments in healthcare, particularly in GCC countries. Furthermore, the rising incidence of autoimmune diseases and cancer is driving the demand for cytokine-based treatments, which is impelling market expansion. According to an industry report, the incidence of cancer in Saudi Arabia is rising significantly. Projections suggest a significant rise in new cases, from 27,885 in 2020 to an anticipated 60,429 by 2040, representing a staggering 116.7% rise. Additionally, growing collaborations between regional biotech companies and global pharmaceutical firms are fostering innovation in cytokine therapies. Besides this, continual advancements in healthcare infrastructure, alongside a focus on improving patient care, are facilitating the adoption of cytokine therapies across the region.

Competitive Landscape:

The market is dominated by a combination of mature pharmaceutical businesses and new biotech companies. These companies are engaged in the advancement and marketing of cytokine-based treatments aimed at diverse diseases, such as cancer, autoimmune diseases, and inflammatory diseases. The industry is very dynamic, with businesses specializing in novel therapeutic approaches, such as cytokine inhibitors, recombinant cytokines, and engineered cytokine-based treatments. Strategic partnerships, collaborations, and acquisitions are the norm as businesses strive to advance their product pipelines and gain competitive advantages in this evolving market. The cytokine market forecast projects that the market will witness tremendous growth in the coming years, fueled by developments in immunotherapy, the increased prevalence of chronic diseases, and heightened healthcare needs. In addition, one of the major trends propelling competition is the growing investment in research and development (R&D) to meet unmet medical needs, particularly for orphans and challenging diseases. Clinical trial success and regulatory approvals are key drivers determining the position in the market for players.

The report provides a comprehensive analysis of the competitive landscape in the cytokine market with detailed profiles of all major companies, including:

AbbVie Inc.
Abcam plc
Amgen Inc.
Applied Biological Materials Inc. (abm)
Bio-Techne Corporation
F. Hoffmann-La Roche AG
GenScript Biotech Corporation
Randox Laboratories Ltd.
Thermo Fisher Scientific Inc.
UCB S.A.

Key Questions Answered in This Report

1.How big is the cytokine market?
2.What is the future outlook of the cytokine market?
3.What are the key factors driving the cytokine market?
4.Which region accounts for the largest cytokine market?
5.Which are the leading companies in the global cytokine market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cytokine Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Cytokine Type

6.1 Tumor Necrosis Factor-TNF
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Interleukins-Il
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Interferons-IFN
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Epidermal Growth Factor-EGF
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Therapeutic Application

7.1 Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Asthma and Airway Inflammation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Arthritis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Contract Research Organizations
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Academic and Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Abcam plc
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Amgen Inc.
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
- 14.3.4 Applied Biological Materials Inc. (abm)
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
- 14.3.5 Bio-Techne Corporation
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
- 14.3.6 F. Hoffmann-La Roche AG
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
- 14.3.7 GenScript Biotech Corporation
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
- 14.3.8 Randox Laboratories Ltd.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
- 14.3.9 Thermo Fisher Scientific Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 UCB S.A.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials

简介目录图表

List of Figures

Figure 1: Global: Cytokine Market: Major Drivers and Challenges
Figure 2: Global: Cytokine Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Cytokine Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Cytokine Market: Breakup by Cytokine Type (in %), 2024
Figure 5: Global: Cytokine Market: Breakup by Therapeutic Application (in %), 2024
Figure 6: Global: Cytokine Market: Breakup by End User (in %), 2024
Figure 7: Global: Cytokine Market: Breakup by Region (in %), 2024
Figure 8: Global: Cytokine (Tumor Necrosis Factor-TNF) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Cytokine (Tumor Necrosis Factor-TNF) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Cytokine (Interleukins-Il) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Cytokine (Interleukins-Il) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Cytokine (Interferons-IFN) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Cytokine (Interferons-IFN) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Cytokine (Epidermal Growth Factor-EGF) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Cytokine (Epidermal Growth Factor-EGF) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Cytokine (Other Cytokine Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Cytokine (Other Cytokine Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Cytokine (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Cytokine (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Cytokine (Asthma and Airway Inflammation) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Cytokine (Asthma and Airway Inflammation) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Cytokine (Arthritis) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Cytokine (Arthritis) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Cytokine (Other Therapeutic Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Cytokine (Other Therapeutic Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Cytokine (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Cytokine (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Cytokine (Contract Research Organizations) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Cytokine (Contract Research Organizations) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: Global: Cytokine (Academic and Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: Global: Cytokine (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: North America: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: North America: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: United States: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: United States: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Canada: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Canada: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: Asia-Pacific: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: Asia-Pacific: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: China: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: China: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: Japan: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: Japan: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: India: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: India: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: South Korea: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: South Korea: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Australia: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Australia: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Indonesia: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Indonesia: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Others: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Others: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Europe: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Europe: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: Germany: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: Germany: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: France: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: France: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: United Kingdom: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: United Kingdom: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Italy: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Italy: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Spain: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Spain: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Russia: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Russia: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Others: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Others: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Latin America: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Latin America: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Brazil: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Brazil: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Mexico: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Mexico: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Others: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Others: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 78: Middle East and Africa: Cytokine Market: Sales Value (in Million USD), 2019 & 2024
Figure 79: Middle East and Africa: Cytokine Market: Breakup by Country (in %), 2024
Figure 80: Middle East and Africa: Cytokine Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Global: Cytokine Industry: SWOT Analysis
Figure 82: Global: Cytokine Industry: Value Chain Analysis
Figure 83: Global: Cytokine Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Cytokine Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Cytokine Market Forecast: Breakup by Cytokine Type (in Million USD), 2025-2033
Table 3: Global: Cytokine Market Forecast: Breakup by Therapeutic Application (in Million USD), 2025-2033
Table 4: Global: Cytokine Market Forecast: Breakup by End User (in Million USD), 2025-2033
Table 5: Global: Cytokine Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Cytokine Market: Competitive Structure
Table 7: Global: Cytokine Market: Key Players

02-2729-4219

+886-2-2729-4219

License/价格

细胞激素市场规模、份额、趋势及预测（按细胞激素类型、治疗应用、最终用户和地区），2025 年至 2033 年

Cytokine Market Size, Share, Trends and Forecast by Cytokine Type, Therapeutic Application, End User, and Region, 2025-2033

细胞激素市场趋势：

目录

第一章：前言

第二章：范围与方法

第三章：执行摘要

第四章：简介

第五章：全球细胞激素市场

第六章：市场细分：依细胞激素类型

第七章：市场区隔：依治疗应用

第八章：市场区隔：按最终用户

第九章：市场细分：依地区

第十章：SWOT分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局